LOGIN or REGISTER to access this content
Immediate, and unrestricted free access to all resources
Earn AMA PRA Category 1 Credits™ for completing accredited activities
Bi-weekly scientific newsletters highlighting the latest emerging data and industry news
Access to your personalised learning profile and CME record.
Clinical specialists from Europe and the USA discuss the management of cholesterol in patients with high low-density lipoprotein cholesterol (LDL-C). The importance of using a high dose of a statin is emphasized especially in patients at high risk.
The information in this activity is intended for healthcare professionals involved in the treatment of patients with high LDL-C levels.
This EXPERT BRIEFING was recorded during the ESC Congress 2019, Paris, France.
After watching this touchEXPERT BRIEFING, you should be able to:
Understand the importance of the ACC/AHA 2018 and ESC 2019 guidelines for management of blood cholesterol/dyslipidaemias with respect to clinical practice
Know the risks and benefits of statin treatment with respect to the risk for type 2 diabetes
Understand the potential for abnormal liver function and metabolic syndrome and be aware of drug-drug interaction as most statins are metabolized via the cytochrome P450 pathway
Know that the PROVE IT and REAL-CAD trials show that high-dose statin therapy is superior to moderate or low dose in cardiovascular event reduction
Understand that combination therapy gives an additional reduction in LDL levels and that statin dose should be titrated to risk
Grundy SM, et al. Circulation 2018;139:e1082-1143.
Mach F, et al. Eur Heart J 2019;00:178.
Stone NJ, et al. J Amer Coll Cardiol 2014;63:2889-934.
Catapano AL, et al. Eur Heart J 2016;37:2999-3058.
Haffner SM, et al. Diabetes 1992;41:715-22.
Haffner SM, et al. JAMA 1990;263: 2893-8.
Sattar N, et al. Circulation 2003;108:414-9.
Feeman WE. Circulation 2004;109:e23.
Sattar N, et al. Lancet 2010;375:735-42.
Preiss D, et al. JAMA 2011;305:2556-64.
Ridker PM, et al. Lancet 2012;380:565-71.
Vallejo-Vaz AJ, Atherosclerosis 2015;241:409-18.
Rowan CG, et al. Pharmacoepidemiol Drug Saf 2012;21:494-506.
Pitavastatin prescribing information.
https://www.kowapharma.com/documents/LIVALO_PI_CURRENT.pdf Athyros VG, at al. Lancet 2010;376:1916-22.
CTT collaborators. Lancet 2012;280:581-90.
Mach F, et al. Eur Heart J 2020;41:111-88.
Cannon CP, et al. NEJM 2015;372:2387-97.
Taguchi I, et al. Circulation 2018;137:1997-2009.
Giugliano RP, et al. Circulation 2018;137:1571-82.
Giugliano RP, et al. Lancet 2017;390:1962-71.
Boekholt SM, et al. J Am Coll Cardiol 2014;64:485-94.
Sabatine MS, et al. NEJM 2017;376:1713-22.
Schwartz GC, et al. NEJM 2018;379:2097-2107.
PROFESSOR ALBERICO CATAPANO
GUIDELINES UPDATE – WHERE ARE WE NOW?
Professor Alberico Catapano discusses the recent American and European guidelines on lipid-lowering therapies, differences between them, challenges in adhering to them, and implications for clinical practice.
Alberico Catapano PhD, is Full Professor of Pharmacology at the University of Milano, Director of Lipid and Atherosclerosis Center at the University of Milan, Department of Pharmacological and Biomolecular Sciences and Multimedica IRCCS, Milan, Italy.
He has made landmark observations regarding the role of HSPs and of pentraxins in atherogenesis and on the role of HDL in the modulation of the immune response. He is Chairman of the EAS/ESC guidelines for the treatment of dyslipoproteinemias.
Professor Catapano has received research grants/support from and/or served as a member of speaker bureaux and/or has received honoraria and/or acted as a consultant and/or served on advisory boards for: Akcea, Aegerion, Amgen, Amryt, Astrazeneca, Eli Lily, Esperion, Genzyme, Ionis Pharmaceuticals, Kowa Pharmaceuticals America Inc., Medco, Menarini, MSD, Mylan, Novartis, Recordati, Regeneron, Daiichi Sankyo and Sanofi.
Please feedback on this touchEXPERT BRIEFING on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).
This activity has been funded by Kowa Pharmaceuticals America Inc. and is provided by Touch Medical Communications (TMC).
TMC activities are developed in conjunction with expert faculty to help fulfil the educational needs of the medical community. The views and opinions expressed are those of the faculty and do not necessarily reflect those of Kowa Pharmaceuticals America Inc.
Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by TMC to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by TMC of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in TMC activities. TMC accepts no responsibility for errors or omissions.
Launch date: June 2020